Menu Close

Lyell Wealth Management LP Has $787,000 Holdings in Johnson & Johnson (NYSE:JNJ)

view original post

Lyell Wealth Management LP grew its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 6.4% in the first quarter, Holdings Channel.com reports. The institutional investor owned 4,443 shares of the company’s stock after buying an additional 269 shares during the quarter. Lyell Wealth Management LP’s holdings in Johnson & Johnson were worth $787,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Patron Partners LLC lifted its position in shares of Johnson & Johnson by 12.7% during the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after purchasing an additional 747 shares during the last quarter. Tandem Investment Advisors Inc. raised its holdings in Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares in the last quarter. Argent Advisors Inc. raised its holdings in Johnson & Johnson by 6.6% in the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after acquiring an additional 1,218 shares in the last quarter. Exeter Financial LLC raised its holdings in Johnson & Johnson by 3.2% in the 1st quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after acquiring an additional 819 shares in the last quarter. Finally, Fusion Capital LLC raised its holdings in Johnson & Johnson by 7.8% in the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after acquiring an additional 2,019 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on JNJ shares. Credit Suisse Group upped their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. SVB Leerink decreased their price target on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. The Goldman Sachs Group increased their price target on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Finally, UBS Group decreased their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Down 0.6 %

Shares of JNJ opened at $172.92 on Wednesday. The firm has a market capitalization of $455.02 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 3.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The business’s fifty day moving average price is $175.67 and its two-hundred day moving average price is $174.49. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $2.48 EPS. On average, analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.